Lmr Partners LLP Arbutus Biopharma Corp Transaction History

Lmr Partners LLP

$10.2 Billion
Q2 2024

A detailed history of Lmr Partners LLP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Lmr Partners LLP holds 255,401 shares of ABUS stock, worth $1.01 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

255,401

Previous 60,000 325.67%

Holding current value

$1.01 Million

Previous $154,000 412.34%

% of portfolio

0.01%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.52 - $3.63 $492,410 - $709,305	195,401 Added 325.67%	255,401 $789,000
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $4,507 - $6,774	2,667 Added 4.65%	60,000 $150,000
Q2 2023 Aug 14, 2023	SELL	$2.24 - $3.06 $5,974 - $8,161	-2,667 Reduced 4.45%	57,333 $131,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $11,574 - $17,271	6,060 Added 11.23%	60,000 $139,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $11,998 - $19,210	-6,060 Reduced 10.1%	53,940 $146,000
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $186,600 - $276,600	60,000 New	60,000 $233,000
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $105,427 - $148,020	-42,171 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$3.14 - $4.84 $190,265 - $293,274	-60,594 Reduced 58.96%	42,171 $140,000
Q4 2020 Feb 16, 2021	SELL	$2.76 - $4.97 $14,205 - $25,580	-5,147 Reduced 4.77%	102,765 $365,000
Q2 2020 Aug 14, 2020	BUY	$0.91 - $2.36 $98,199 - $254,672	107,912 New	107,912 $196,000
Q4 2019 Feb 14, 2020	SELL	$0.87 - $2.89 $25,320 - $84,110	-29,104 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $42,491 - $129,221	29,104 New	29,104 $61,000

Others Institutions Holding ABUS

# of Institutions

138

Shares Held

95.4M

Call Options Held

3.44M

Put Options Held

377K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $591M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Account